Get started
Author

Barbara Di Cocco

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
2020 · Alessio Cortellini, Marco Tucci, et al. · Journal for ImmunoTherapy of Cancer · 272
PDF
Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients
2005 · Gianluigi Ferretti, Alessandra Fabi, et al. · Oncology · 132
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
2020 · Sebastiano Buti, Melissa Bersanelli, et al. · European Journal of Cancer · 112
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
2006 · P. Papaldo, A. Fabi, et al. · Annals of Oncology · 81
PDF
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
2017 · Patrizia Vici, Laura Pizzuti, et al. · Oncotarget · 69
PDF
Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases.
2006 · Nello Salesi, Roberto Pistilli, et al. · PubMed · 29
Hamartomatous Polyposis Syndromes
2015 · Giandominik Bossone, Nello Salesi, et al. · Elsevier eBooks · 26
Testis metastasis as an initial manifestation of an occult gastrointestinal cancer.
2004 · Nello Salesi, Alessandra Fabi, et al. · PubMed · 22
Biosimilar Medicines in Oncology: Single-Center Experience with Biosimilar G-CSF
2012 · Nello Salesi, Barbara Di Cocco, et al. · Future Oncology · 16
Clinical experience with bevacizumab in colorectal cancer.
2005 · Nello Salesi, Giandominik Bossone, et al. · PubMed · 13
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
2019 · Laura Pizzuti, Eriseld Krasniqi, et al. · International Journal of Cancer · 10
PDF
Choroid plexus carcinoma in the adult: is there a role for chemotherapy?
2005 · A Fabi, N Salesi, et al. · PubMed · 6
Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality
2005 · G. Ferretti, E. Bria, et al. · Journal of Clinical Oncology · 5
Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
2005 · A. Fabi, G. Ferretti, et al. · Annals of Oncology · 4
Bisphosphonates and oral cavity avascular bone necrosis: A review of 12 cases
2006 · N. Salesi, R. Pistilli, et al. · Journal of Clinical Oncology · 3
13 Sequential chemotherapy in non-small cell lung cancer (NSCLC): Cisplatin and gemcitabine (P/G) followed by docetaxel (D)
2003 · Anna Ceribelli, Michele Milella, et al. · Lung Cancer · 2
P-627 Results from compassionate use of gefitinib (Iressa) in progressive pretreated non small cell lung cancer (NSCLC): our experience
2003 · Maria S. Pino, Alain Gelibter, et al. · Lung Cancer · 2
[A new drug in the therapy of chronic myeloid leukemia: ST1571].
2003 · N Salesi, G Bossone, et al. · PubMed · 2
Celecoxib combined with fixed dose-rate gemcitabine (FDR-Gem)/CDDP as induction chemotherapy for stage III non-small cell lung cancer (NSCLC)
2005 · M. Milella, A. Ceribelli, et al. · Journal of Clinical Oncology · 1
Alfa-epoietin and anaemia in gynaecological cancer.
2004 · Barbara Di Cocco, Nello Salesi, et al. · PubMed · 1
[Testis cancer markers. Clinical use].
2002 · N Salesi, B Di Cocco, et al. · PubMed · 1
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort
2025 · Jessica Lucchetti, Lorenzo Angotti, et al. · Clinical Colorectal Cancer
PDF
258P The impact of total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC): A real-world Italian multicentric experience
2024 · F. Lo Prinzi, V. Picone, et al. · Annals of Oncology
PDF
P-236 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023 · J. Lucchetti, L. Angotti, et al. · Annals of Oncology
PDF
P-249 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023 · L. Angotti, J. Lucchetti, et al. · Annals of Oncology
Works count: 33
Citation count: 809
H-index: 10
I10-index: 11
Year
Topic
Type